Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase 2 open-label tislelizumab study in relapsed or refractory mature T- and NK-cell neoplasms
2017-003700-44Phase 2Completed
- Sponsor
- BeiGene
- Start
- Jan 2018
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of tislelizumab in mature T-cell and natural killer cell neoplasm and T-cell lymphoma, sponsored by BeiGene. Primary endpoint: Overall response rate. Started Jan 2018; status: completed.
02
Drugs
tislelizumab
03
Conditions
mature T-cell and natural killer cell neoplasmT-cell lymphoma
Beyond the preview
Go deeper on 2017-003700-44.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2017-003700-44.